Antiviral Deal Benchmarks in Infectious Disease

Median Upfront

$664M

Range: $387M - $920M

Total Deal Value

$2.5B

Range: $1.7B - $3.4B

Royalty Rate

8.4% - 16.7%

Tiered up to 20.7%

Dev Milestones

$413M

Range: $295M - $536M

Model Your Deal

Market Analysis

Antiviral therapies in infectious disease have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 antiviral asset in infectious disease is $664M, with total deal values reaching $2.5B. Development milestones average $413M, while regulatory milestones contribute $432M.

The infectious disease antiviral landscape is characterized by variable competitive intensity across pathogen types, with high activity in antiviral and AMR spaces. MRNA platforms, novel antibiotics addressing resistance, and pandemic preparedness assets sustain strong licensee demand. The recommended deal structure allocates approximately 26% to upfront payments and 74% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for antiviral infectious disease deals range from 8.4% to 16.7% at the base tier, with tiered escalation reaching 12.4%-20.7% on blockbuster sales. Commercial milestones averaging $1.0B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a antiviral infectious disease licensing deal?

Based on our analysis, Phase 2 antiviral licensing deals in infectious disease average $664M in upfront payments, with a range of $387M to $920M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for antiviral infectious disease transactions?

The median total deal value for Phase 2 antiviral assets in infectious disease is $2.5B, ranging from $1.7B to $3.4B. This includes development milestones ($413M), regulatory milestones ($432M), and commercial milestones ($1.0B).

What royalty rates are standard for antiviral deals in infectious disease?

Base royalty rates for antiviral infectious disease transactions range from 8.4% to 16.7%, with tiered escalations reaching 12.4%-20.7% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in antiviral infectious disease deals?

Antiviral infectious disease deals allocate approximately 74% of total deal value to milestones. Development milestones ($413M) make up the largest share, followed by commercial milestones ($1.0B) and regulatory milestones ($432M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Infectious Disease

View

Monoclonal Antibody in Infectious Disease

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included